Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

192 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Kong YY, et al. Nature. 1999 Nov 18;402(6759):304-9. doi: 10.1038/46303. Nature. 1999. PMID: 10580503
Generalized Degenerative Joint Disease in Osteoprotegerin (Opg) Null Mutant Mice.
Bolon B, Grisanti M, Villasenor K, Morony S, Feige U, Simonet WS. Bolon B, et al. Vet Pathol. 2015 Sep;52(5):873-82. doi: 10.1177/0300985815586221. Epub 2015 May 27. Vet Pathol. 2015. PMID: 26018435
Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses.
Stolina M, Dwyer D, Ominsky MS, Corbin T, Van G, Bolon B, Sarosi I, McCabe J, Zack DJ, Kostenuik P. Stolina M, et al. J Immunol. 2007 Dec 1;179(11):7497-505. doi: 10.4049/jimmunol.179.11.7497. J Immunol. 2007. PMID: 18025194
Analysis of the kinetics of osteoclastogenesis in arthritic rats.
Schett G, Stolina M, Bolon B, Middleton S, Adlam M, Brown H, Zhu L, Feige U, Zack DJ. Schett G, et al. Arthritis Rheum. 2005 Oct;52(10):3192-201. doi: 10.1002/art.21343. Arthritis Rheum. 2005. PMID: 16200623
Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
Schett G, Middleton S, Bolon B, Stolina M, Brown H, Zhu L, Pretorius J, Zack DJ, Kostenuik P, Feige U. Schett G, et al. Arthritis Rheum. 2005 May;52(5):1604-11. doi: 10.1002/art.21021. Arthritis Rheum. 2005. PMID: 15880601
Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Görtz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen JS. Schett G, et al. Arthritis Rheum. 2003 Jul;48(7):2042-51. doi: 10.1002/art.11150. Arthritis Rheum. 2003. PMID: 12847699
Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis.
Coxon A, Bolon B, Estrada J, Kaufman S, Scully S, Rattan A, Duryea D, Hu YL, Rex K, Pacheco E, Van G, Zack D, Feige U. Coxon A, et al. Arthritis Rheum. 2002 Oct;46(10):2604-12. doi: 10.1002/art.10546. Arthritis Rheum. 2002. PMID: 12384918
Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.
Bolon B, Stolina M, King C, Middleton S, Gasser J, Zack D, Feige U. Bolon B, et al. J Biomed Biotechnol. 2011;2011:569068. doi: 10.1155/2011/569068. Epub 2010 Dec 28. J Biomed Biotechnol. 2011. PMID: 21253435 Free PMC article. Review.
The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis.
Stolina M, Bolon B, Dwyer D, Middleton S, Duryea D, Kostenuik PJ, Feige U, Zack DJ. Stolina M, et al. Biomarkers. 2008 Nov;13(7):692-712. doi: 10.1080/13547500802651911. Biomarkers. 2008. PMID: 19096963
192 results
Jump to page
Feedback